Jose Zaglul, MD
Psychiatry · Bradenton, FLNPI 1225024763
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,994 of the $10,598 with a category attached, or 75.4%. 18 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 52.7% of the total. Reporting peaked in 2024 at $8,319 and has fallen 97.8% since, to $182 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $116.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$6K
- Boehringer Ingelheim$3K
- AbbVie$475
- Johnson & Johnson$267
- Ironshore Pharmaceuticals Inc.$266
- Tris Pharma Inc$245
- plus $1K from 12 others
Across 36 payments — averaging $2803.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Supernus Pharmaceuticals, Inc.$82K
- AbbVie$14K
- Rhodes Pharmaceuticals L.p.$4K
- Neurocrine Biosciences, Inc.$500
- Sunovion Pharmaceuticals Inc.$1
What the payments were for
- Consulting fees$7,99475%
- Food & beverage$2,56124%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $5,581 |
| Boehringer Ingelheim | 2 | $2,625 |
| AbbVie(2 entities) | 28 | $475 |
| Johnson & Johnson | 10 | $267 |
| Ironshore Pharmaceuticals Inc. | 4 | $266 |
| Tris Pharma Inc | 3 | $245 |
| Neurocrine Biosciences, Inc. | 5 | $220 |
| Corium, LLC | 6 | $191 |
| Alkermes, Inc. | 9 | $167 |
| E.r. Squibb & Sons, L.L.C. | 2 | $115 |
| Jazz Pharmaceuticals Inc. | 1 | $106 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $97 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $88 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Indivior Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,598 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $85,832 |
| Invega SustennaPaliperidone Palmitate | 20 | $63,365 |
| Risperdal ConstaRisperidone Microspheres | 13 | $36,439 |
| RexultiBrexpiprazole | 13 | $21,302 |
| Aripiprazole | 77 | $6,281 |
| Olanzapine | 105 | $5,135 |
| Fluphenazine Hcl | 26 | $4,753 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $4,499 |
| Divalproex Sodium ErDivalproex Sodium | 39 | $2,612 |
| Haloperidol Decanoate | 48 | $2,563 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 63 | $2,320 |
| Donepezil Hcl | 13 | $2,119 |
| Duloxetine Hcl | 69 | $1,858 |
| Clonazepam | 140 | $1,806 |
| Quetiapine Fumarate | 50 | $1,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $267 | $99,80433 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $5,581 | $85,83215 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $58 | $21,30213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Bradenton
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.